Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis
M. Watanabe (Kochi, Japan), Y. Horimasu (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Kohno (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Watanabe (Kochi, Japan), Y. Horimasu (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Kohno (Hiroshima, Japan), N. Hattori (Hiroshima, Japan). Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis. 3600
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Prognostic characteristics in chronic hypersensitivity pneumonitis. Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019
Prognostic factors in chronic hypersensitivity pneumonitis Source: Eur Respir Rev, 29 (156) 190167; 10.1183/16000617.0167-2019 Year: 2020
Diagnostic and prognostic utility of eosinophilic pleural effusions(PE) Source: Eur Respir J 2002; 20: Suppl. 38, 440s Year: 2002
Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis Source: Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015 Year: 2017
Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis Source: Eur Respir J, 52 (2) 1800443; 10.1183/13993003.00443-2018 Year: 2018
Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Clinical features of dermatitis, myositis and severe ILD. Could the AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom? Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018
Clinical prognostic tools and their use in COPD. Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020
Predictive value of clinical diagnosis in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 345s Year: 2001
Induced sputum TNF-α level as possible prognostic factor in sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 115s Year: 2007
The prognostic value of some clinical and laboratory parameters in sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002
Validation of a novel prognostic tool for idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012
Sarcoidosis: Clinical course and prognostic predictors Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases Year: 2010
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
Relevant prognostic predictors of sarcoidosis course Source: Eur Respir J 2001; 18: Suppl. 33, 345s Year: 2001
Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Clinical diagnosis, monitoring and biomarkers in ILDs Source: ERS Course 2016 Year: 2016
Clinical diagnosis, monitoring and biomarkers in ILDs Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019